You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 379 results found

Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics

The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA  and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology  or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.
  • Therapeutics

Mouse Xenograft Model for Mesothelioma

The National Cancer Institute is seeking parties interested in collaborative research to co-develop, evaluate, or commercialize a new mouse model for monoclonal antibodies and immunoconjugates that target malignant mesotheliomas. Applications of the technology include models for screening compounds as potential therapeutics for mesothelioma and for studying the pathology of mesothelioma.
  • Research Tools

Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors

Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
  • Therapeutics

Modulating Chemotherapeutic Cytotoxicity

The NCI seeks partners interested in in-licensing or co-development collaboration on CD47-targeting therapeutics for cardioprotection and autophagy modulation.
  • Therapeutics

Novel Anti-HIV Proteins from Coral Reefs

Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.
  • Therapeutics

Topical Antibiotic for Faster Wound Healing

Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished.  The National Cancer Institute Laboratory of Experimental Immunology seeks parties interested in licensing a topical antibiotic formulation to accelerate wound healing.
  • Therapeutics

Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds

This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
  • Devices

Synthetic lipopeptide inhibitors of RAS oncoproteins

It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity. NCI’s Cancer and Inflammation Program seeks partners interested in licensing or co-development of synthetic, highly potent cell-permeable inhibitors of Ras that bind to the protein directly.
  • Therapeutics

A peptide hydrogel for use in vascular anastomosis

Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.
  • Devices

Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma

Researchers at NCI have developed a means of more closely simulating in mouse models both melanoma cancer itself and the resulting physiological an immunological response by creating a genetically engineered mice (GEM)-derived allograft (GDA).  This allograft both resembles human-like melanoma and has features that will stimulate a normal immunological response in the mouse.
  • Research Tools

Optical Microscope Software for Breast Cancer Diagnosis

Researchers from NCI and Rudgers University developed  methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell. The National Cancer Institute seeks parties interested in collaborative research to co-develop diagnostic methods for detection of cancer using spatial genome organization.
  • Research Tools
  • Software

Pages